Sotatercept for Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Recruiting
Phase 3
Interventional Study
Pulmonary Arterial Hypertension
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 815 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
Who this trial is looking for
This trial is looking for people who have completed a previous study with sotatercept for pulmonary arterial hypertension (PAH). Participants will be monitored for the long-term safety and tolerance of sotatercept along with their usual PAH treatments.
Are You a Good Fit for This Trial?
You may be able to join if
- I have completed my previous PAH sotatercept study.
- I am willing to attend all study visits.
- I can understand and provide my consent.
You may not be able to join if
- I did not participate in a parent study for sotatercept.
- I missed more than 4 doses after my last study.
- I have an ongoing serious health issue related to sotatercept.
- I am pregnant or breastfeeding.
- I am or have a family member who works with this study.
- I am enrolled in another investigational product study.
- I am incapacitated.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse.
Sotatercept is a s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early
* Is willing to adhere to the study visit schedule, and understands and w…
Contacts